Recently, the journal Therapeutic Advances in Medical Oncology published a retrospective real-world study from the Peking Union Medical College Hospital team, mainly to explore the best first-line chemotherapy-based treatment in patients with HER2-altered advanced NSCLC
.

Recently, the journal Therapeutic Advances in Medical Oncology published a retrospective real-world study from the Peking Union Medical College Hospital team, mainly to explore the best first-line chemotherapy-based treatment in patients with HER2-altered advanced NSCLC
.

Peking Union Medical College Hospital NSCLC

The study included patients with HER2-altered advanced NSCLC who received first-line therapy between November 2015 and September 2021
.

According to the treatment methods, patients are divided into: chemotherapy alone (C), chemotherapy combined with immunotherapy (C+I) or chemotherapy combined with antiangiogenic therapy (C+A)

The study included patients with HER2-altered advanced NSCLC who received first-line therapy between November 2015 and September 2021

A total of 293 patients were screened and 37 distinct HER2 mutations were identified, with the most common variant subtype being exon 20 insertions (ex20ins, n=246, 83.

KEGG analysis revealed that the PI3k/AKT signaling pathway was generally upregulated in HER2-altered NSCLC
.

KEGG analysis revealed that the PI3k/AKT signaling pathway was generally upregulated in HER2-altered NSCLC
.

Finally, 210 first-line chemotherapy-based patients were included, of which 83 (39.
5%), 81 (38.
6%), and 46 (21.
9%) were treated with C, C+I, or C+A, respectively
.

ORR, DCR, median PFS and median OS in arm C were 16.

Finally, 210 first-line chemotherapy-based patients were included, of which 83 (39.

A significant difference in PFS was observed between C+A and C subgroups (median, 5.
63 vs 4.
03 months, HR=0.
64, 95% CI: 0.
46-0.
88, p=0.
006)
.

There was no statistical difference in PFS between C+I and C subgroups ( median, 5.

A significant difference in PFS was observed between C+A and C subgroups (median, 5.

Among the 19 patients who obtained PD-L1 expression status, the ORR of 5 patients with negative TPS was 20% (1/5), and the median PFS was 7.

Taken together, these studies suggest that chemotherapy combined with anti-vascular survival therapy may be more effective in patients with advanced HER2-altered NSCLC
.

Taken together, these studies suggest that chemotherapy combined with anti-vascular survival therapy may be more effective in patients with advanced HER2-altered NSCLC
.

Studies have shown that chemotherapy combined with anti-vascular survival therapy may be better in patients with advanced HER2-altered NSCLC

Original source:

Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, Li J, Xing P, Zhang S, Ai X, Xu F, Wang Y.

Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, Li J, Xing P, Zhang S, Ai X, Xu F, Wang Y.
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC : a retrospective real-world POLISH study.
Ther Adv Med Oncol.
2022 Mar 2;14:17588359221082339.
doi: 10.
1177/17588359221082339.
PMID: 35251321; PMCID: PMC8894956.
  Yang G, Yang Y, Liu R, Li W, Xu H , Hao X, Li J, Xing P, Zhang S, Ai X, Xu F, Wang Y.
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 HER2 -altered NSCLC: a retrospective real-world POLISH study.
Ther Adv Med Oncol .
2022 Mar 2;14:17588359221082339.
doi: 10.
1177/17588359221082339.
PMID: 35251321; PMCID: PMC8894956.
Leave a message here